We're excited to share an important update for the spinal muscular atrophy (SMA) community. The U.S. Food and Drug Administration (FDA) has approved a label expansion for Evrysdi® (risdiplam) tablets, effective February 10, 2026. The tablet formulation is now approved for administration via nasogastric (NG) or gastrostomy (G) feeding tubes after dispersion in water. This update removes a meaningful barrier and extends access to the Evrysdi® tablet for a broader patient population.
This expanded label is an important step forward because it gives families and healthcare providers additional flexibility when considering treatment options. For individuals who rely on feeding tubes for medication delivery, this approval helps ensure that more people living with SMA can receive care that fits their individual needs.
We also want to share a new drug interaction update. A study in healthy volunteers examined whether taking omeprazole — a common acid-reducing medication used to treat acid reflux — at the same time as risdiplam affects how the drug works in the body. The study found no clinically significant differences. Based on these results, no changes in how risdiplam works are expected when taken alongside other acid-reducing agents, including H2-receptor antagonists and antacids.
Progress like this is made possible through the dedication of researchers, clinicians, advocates, donors, and those who participated in clinical trials. Cure SMA remains committed to working closely with healthcare providers, researchers, and the SMA community to help ensure families have clear information and access to available treatment options.
If you have questions or would like support understanding what this expanded access may mean for you or your loved one, please contact our team at [email protected].